responsive

Q BioMed Inc. 'Q' is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued and under-appreciated biomedical assets. Q is dedicated to providing these target assets, the strategic resources, developmental support, and expansion capital to ensure they meet their potential. The end result being value recognition and ultimately enabling them to provide products to patients in need‏.

 QBIO 4,01 -0,12 -2,91%

Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our assets’ technologies to monetization.”

Qbio's Biotechnology

CEO Denis Corin NEW 2017 Interview

Looking for Shareholder Returns

The right firm

Q focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.

The right solution

Our team aims to assist companies by utilizing our investment partners and network of experts to provide public market access to private company assets.  80% of biomedical start ups lack capital and resources to transition from incubation to development and beyond.

The right strategy

Q expects to maximize risk-adjusted returns by focusing on value driven assets from early stage to near revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.

Social media & sharing icons powered by UltimatelySocial